Search

Displaying results 5091 - 5100 of 10000 in total
  1. Drug

    Oral Polio Vaccine

    go.drugbank.com/drugs/DB15864
    Investigational

    The polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are … Strains of the virus are selected based on their reduced incidence of spreading to the central nervous system but still having the ability to mimic the immune response that occurs after infection with

  2. Drug

    Rosoxacin

    go.drugbank.com/drugs/DB00817
    Approved

    Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. … Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin,

  3. Drug

    PF-05241328

    go.drugbank.com/drugs/DB15124
    Investigational

    PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound … Which Will Not Have Any Pharmacological Activity).

  4. Drug

    Benactyzine

    go.drugbank.com/drugs/DB09023
    ApprovedWithdrawn

    Benactyzine is an anticholinergic drug used as an antidepressant in the treatment of depression and associated anxiety. … It does not possess any antihistamine properties.

  5. Drug

    Enlicitide

    go.drugbank.com/drugs/DB22580
    ApprovedInvestigational

    (CORALreef Lipids), and by 59% in patients with HeFH (CORALreef HeFH), with comparable reductions in non-HDL-C and apolipoprotein B. … [L63795] Enlicitide was developed by Merck Sharp & Dohme and received initial U.S. approval in 2026, marketed under the trade name LIPFENDRA.[L63795]

  6. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Then, the medium is filtered and separated from the HUCBCs. … After the human umbilical cord mononuclear cells are extracted from the umbilical cord, they are expanded and cultured in Dulbecco’s modified Eagle’s medium.

  7. Drug

    CCX915

    go.drugbank.com/drugs/DB05159
    Experimental

    CCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders. … The CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis.

  8. Drug

    Genistein

    go.drugbank.com/drugs/DB01645
    Investigational

    An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. … Natural sources of genistein include tofu, fava beans, soybeans, kudzu, and lupin.

    Categories: Hormones, Hormone Substitutes, and Hormone Antagonists
  9. Drug

    Secretin porcine

    go.drugbank.com/drugs/DB09527
    ApprovedWithdrawn

    Secretin porcine stimulates pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine dysfunction and the diagnosis of gastrinoma.

  10. Drug

    XL228

    go.drugbank.com/drugs/DB05184
    Investigational

    , survival and metastasis. … XL228 is a novel anticancer compound designed to inhibit the insulin-like growth factor type-1 receptor (IGF1R), Src and Abl tyrosine kinases – targets that play crucial roles in cancer cell proliferation